General Secretary To Lam witnessed the handover ceremony of cooperation documents between VNVC and GSK in the UK.

On the afternoon of October 30, in London, Vietnam Vaccine Company VNVC and GSK Vietnam, part of the GSK - UK biopharmaceutical group, exchanged documents to upgrade strategic cooperation on access to new drugs and vaccines, scientific research and exchanges on vaccine production.

The document handover ceremony was witnessed by General Secretary To Lam and British Government Trade Envoy Matt Western. The event took place within the framework of General Secretary To Lam's official visit to the United Kingdom of Great Britain and Northern Ireland and the upgrading of Vietnam-UK relations to a Comprehensive Strategic Partnership.

General Secretary To Lam and British Government Trade Envoy Matt Western witnessed Mr. Ngo Chi Dung, Chairman of the Board of Directors and General Director of Vietnam Vaccine Company VNVC and Ms. Kaja Natland, Senior Vice President of GSK Asia- Pacific and International Region, exchanging documents to upgrade cooperation. Photo: HTN

According to the signed content, VNVC and GSK will cooperate to promote rapid access to advanced drugs and vaccines developed by GSK, especially to bring new specific drugs and vaccines produced at GSK's modern, global strategic factories in Worthing and Barnard Castle (UK) to Vietnam. In addition, the two sides will also cooperate in scientific research and exchange experiences in vaccine production so that VNVC can be self-sufficient in production and supply at its factory in Vietnam.

In particular, VNVC Vietnam is very interested in accessing new vaccines, antibiotics and new generation cancer drugs being produced by GSK.

The signing is expected to open up cooperation opportunities worth an estimated £500 million (approximately VND17,000 billion) over the next five years, while promoting clinical research cooperation and the exchange of knowledge and good practices in vaccine production.

The cooperation agreement between VNVC and GSK focuses on increasing early access to new drugs and vaccines for the Vietnamese people, while promoting scientific research and exchanges on vaccine production. Photo: Ha Ngan

At the document exchange within the framework of the Vietnam-UK High-Level Economic Conference, General Secretary To Lam outlined three key areas of cooperation between Vietnam and the UK in the new era. Accordingly, the first focus is to promote research and development (R&D) cooperation between universities and research institutes of businesses of the two countries specializing in research on the application of artificial intelligence (AI), big data, smart energy, healthcare, chemical engineering and strategic transformational technologies. Second, to increase investment and exchange of senior experts, promote the development of AI applications and digital transformation in key economic sectors. Third, to support businesses of the two countries to expand investment, share data and implement comprehensive technology cooperation programs.

The General Secretary affirmed that Vietnam is ready to be a reliable partner of the UK in technology development and innovation, bringing practical values ​​to the people of both countries and making positive contributions to the region and the world. The two governments will also strengthen coordination, encourage forms of cooperation, research, training and technology transfer, contributing to deepening the Vietnam-UK Comprehensive Strategic Partnership.

Previously, in October 2025 in Ho Chi Minh City, with the witness of the British Deputy Consul General in Ho Chi Minh City, Vietnam Vaccine Company VNVC, Tam Anh General Hospital System and GSK Vietnam Pharmaceutical Company had a high-level delegation working program and signed a memorandum of understanding on cooperation in accessing new drugs and vaccines, promoting clinical research as well as exchanging knowledge in vaccine production.

The signing ceremony of the strategic cooperation memorandum between VNVC - Tam Anh - GSK took place under the witness of Deputy Consul General of the UK in Ho Chi Minh City William Lawrenson in Ho Chi Minh City, October 2025. Photo: Thanh Luan

The document handover ceremony in London this time is a testament to the consolidation and elevation of the strategic cooperation relationship between the parties before the high-ranking leaders of the two countries, aiming to improve the quality of healthcare for the Vietnamese people from prevention to treatment, contributing to realizing the aspiration of building Vietnam into a center for research, development, application and innovation of biopharmaceutical technology in the region.

Mr. Ngo Chi Dung, Chairman of the Board of Directors and General Director of Vietnam Vaccine Company VNVC and VNVC Vaccine and Biological Factory, said that VNVC and GSK have had a comprehensive strategic partnership, coordinating to bring to Vietnam many new generation vaccines, contributing significantly to ending the shortage of vaccines for children and adults in Vietnam.

In the past 5 years, the VNVC - Tam Anh Healthcare Ecosystem has had commercial cooperation, training to improve medical personnel capacity and other activities with GSK, worth nearly 400 million pounds (more than 13,000 billion VND) and continues to grow every year. Along with the development of the VNVC Vaccination System, GSK vaccines have become popular and occupy the largest market share among pharmaceutical companies in the market of more than 100 million people in Vietnam.

Mr. Ngo Chi Dung emphasized: “Elevating cooperation helps Vietnam solve problems in vaccine supply through trade cooperation, proactively accessing early and remotely advanced biopharmaceutical products such as new antibiotics, new cancer drugs and especially accessing knowledge in vaccine production so that Vietnam can move towards self-sufficiency in production, domestic supply and export.”

The VNVC Vaccine and Biological Factory has an initial scale of more than VND2,500 billion in Tay Ninh province, invested with modern world technologies, and started construction in May 2025. Photo: VNVC

Ms. Kaja Natland, Senior Vice President of GSK Asia Pacific, International, said: “The strategic cooperation with VNVC in the coming years will play a key role in expanding access to the world's advanced healthcare solutions such as specialty drugs, cancer drugs, effectively implementing lifelong vaccination programs and promoting clinical research. GSK aims to work with VNVC to achieve the common goal of creating a positive impact on the health of more than one-third of Vietnam's population in the next 5 years, in line with GSK's mission of combining science, technology and talent to defeat disease”.

Over the past 10 years, VNVC has brought to Vietnam many new and new generation vaccines, including GSK's most important ones, helping to protect the health of millions of children and families. Photo: Dieu Thuan

This strategic cooperation between VNVC and GSK in the UK is also of great significance at the present time, demonstrating the development and upgrading of the outstanding relationship between private enterprises representing the two countries in taking advantage of breakthrough policy levers on international cooperation, investment in science and technology development, private economy and strengthening people's health care of the Politburo, Government and Ministry of Health of Vietnam.

Source: https://daibieunhandan.vn/tong-bi-thu-to-lam-chung-kien-le-trao-van-kien-hop-tac-giua-vnvc-va-gsk-tai-anh-10393731.html